Astellas Pharma Inc. · TSE:4503
Astellas Pharma — Q2 2018 Earnings Presentation
5 slides from Astellas Pharma's earnings presentation, October 2018
Slide 1: R&D Pipeline (As of Oct 2018) - Oncology (1/2)
R&D Pipeline (As of Oct 2018) Underlined items indicate changes from the previous announcement on July 27, 2018. Oncology (1/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Generic Name Dosage Code No. Classification Target Disease Phase / Area Licenso
Slide 2: Oncology (2/2)
Oncology (2/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Generic Name Dosage Code No. Classification Target Disease Phase / Area Licensor* Focus Area approach Form (Brand Name) ASP1235/AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC techn
Slide 3: Immunology, Muscle disease and Ophthalmology
Immunology, Muscle disease and Ophthalmology *Compounds with "In-house" in this column include ones discovered by collaborative research. Generic Name Dosage Code No. Classification Target Disease Phase / Area Licensor* Focus Area approach Form (Brand Name) peficitinib JAK inhibitor Rheumatoid arthr
Slide 4: Urology and Nephrology
Urology and Nephrology *Compounds with "In-house" in this column include ones discovered by collaborative research. Generic Name Dosage Code No. Classification Target Disease Phase / Area Licensor* Focus Area Approach Form (Brand Name) solifenacin Muscarine M3 receptor antagonist Neurogenic detrusor
Slide 5: Others
Others *Compounds with "In-house" in this column include ones discovered by collaborative research. Generic Name Dosage Code No. Classification Target Disease Phase / Area Licensor* Focus Area approach Form (Brand Name) linaclotide Guanylate cyclase-C receptor Chronic constipation Approved (Aug. 201
Astellas Pharma — Q2 2018 Earnings Presentation on 6ix